UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2010
ALION SCIENCE AND TECHNOLOGY
CORPORATION
(Exact name of registrant as
specified in its charter)
Delaware | 333-89756 | 54-2061691 | ||
(State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
1750 Tysons
Boulevard Suite 1300 McLean, VA |
22102 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (703) 918-4480
(Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
(Dollars in thousands)
(Unaudited)
Three months | Twelve months | |||||||
ended September | ended September | |||||||
30, 2010 | 30, 2010 | |||||||
Calculation of Consolidated Net Income |
||||||||
Net income/(loss) |
($3,341 | ) | ($15,233 | ) | ||||
Less: Income of any subsidiary to the extent
dividends are not permitted |
0 | 0 | ||||||
Less: Income/(loss) of any subsidiary accrued prior
to close of an acquisition |
0 | 0 | ||||||
Less: Gain/(loss) on asset sales |
(2,594 | ) | (2,594 | ) | ||||
Less: Income/(loss) from early extinguishment of debt |
(0 | ) | (50,749 | ) | ||||
Consolidated Net Income |
($5,935 | ) | ($68,576 | ) | ||||
Calculation of Consolidated EBITDA* |
||||||||
Consolidated Net Income |
($5,935 | ) | ($68,576 | ) | ||||
Plus: Interest expense |
18,338 | 67,613 | ||||||
Plus: Income tax expense |
1,592 | 37,166 | ||||||
Plus: Depreciation and amortization expense |
4,225 | 16,732 | ||||||
Plus: Non-cash expense SAR, Phantom Stock, Warrants |
(318 | ) | (1,150 | ) | ||||
Less: Cash payments SAR, Phantom Stock, Warrants |
0 | (2,202 | )** | |||||
Plus: Non-cash contributions ESOP/401(k) match |
2,383 | 10,127 | ||||||
Less: Cash payments ESOP obligations |
0 | (1,216 | ) | |||||
Plus: Non-cash charges/expenses LTIP |
831 | 4,308 | ||||||
Less: Cash payments non-cash charges/expenses LTIP |
(76 | ) | (3,278) | |||||
Plus: NREs |
975 | 4,413 | ||||||
Consolidated EBITDA |
$ | 22,015 | $ | 63,938 | ||||
2
3
ALION SCIENCE AND TECHNOLOGY CORPORATION |
||||
By: | /s/ Michael J. Alber | |||
Name: | Michael J. Alber | |||
Title: | Chief Financial Officer | |||
4